ContraFect Corporation Company Profile (NASDAQ:CFRX)

About ContraFect Corporation (NASDAQ:CFRX)

ContraFect Corporation logoContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CFRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $76.6 million
  • Outstanding Shares: 73,656,000
Average Prices:
  • 50 Day Moving Avg: $1.06
  • 200 Day Moving Avg: $1.31
  • 52 Week Range: $0.80 - $2.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.48
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.27 per share
  • Price / Book: 3.85
  • EBITDA: ($28,650,000.00)
  • Return on Equity: -188.40%
  • Return on Assets: -84.04%
  • Current Ratio: 6.59%
  • Quick Ratio: 6.59%
  • Average Volume: 155,529 shs.
  • Beta: -0.82
  • Short Ratio: 1.01

Frequently Asked Questions for ContraFect Corporation (NASDAQ:CFRX)

What is ContraFect Corporation's stock symbol?

ContraFect Corporation trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect Corporation's earnings last quarter?

ContraFect Corporation (NASDAQ:CFRX) announced its earnings results on Wednesday, August, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.11. View ContraFect Corporation's Earnings History.

When will ContraFect Corporation make its next earnings announcement?

ContraFect Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for ContraFect Corporation.

Where is ContraFect Corporation's stock going? Where will ContraFect Corporation's stock price be in 2017?

2 analysts have issued 1-year price targets for ContraFect Corporation's stock. Their forecasts range from $5.00 to $5.00. On average, they expect ContraFect Corporation's share price to reach $5.00 in the next year. View Analyst Ratings for ContraFect Corporation.

Who are some of ContraFect Corporation's key competitors?

Who owns ContraFect Corporation stock?

ContraFect Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include FOSUN INDUSTRIAL COMPANY ., LTD (16.40%). Company insiders that own ContraFect Corporation stock include Cara M Cassino, Daniel Couto, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Institutional Ownership Trends for ContraFect Corporation.

How do I buy ContraFect Corporation stock?

Shares of ContraFect Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraFect Corporation's stock price today?

One share of ContraFect Corporation stock can currently be purchased for approximately $1.04.

MarketBeat Community Rating for ContraFect Corporation (NASDAQ CFRX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  139
MarketBeat's community ratings are surveys of what our community members think about ContraFect Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ContraFect Corporation (NASDAQ:CFRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.00 (380.77% upside)
Consensus Price Target History for ContraFect Corporation (NASDAQ:CFRX)
Price Target History for ContraFect Corporation (NASDAQ:CFRX)
Analysts' Ratings History for ContraFect Corporation (NASDAQ:CFRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Maxim GroupReiterated RatingHoldLowView Rating Details
11/21/2016Piper Jaffray CompaniesSet Price TargetBuy$5.00N/AView Rating Details
9/28/2016William BlairInitiated CoverageOutperformN/AView Rating Details
5/10/2016Roth CapitalDowngradeBuy -> Neutral$4.00 -> $3.30N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for ContraFect Corporation (NASDAQ:CFRX)
Earnings by Quarter for ContraFect Corporation (NASDAQ:CFRX)
Earnings History by Quarter for ContraFect Corporation (NASDAQ CFRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.11)N/AView Earnings Details
8/9/2017Q2 2017($0.18)($0.07)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.17)($0.15)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.20)$0.01ViewN/AView Earnings Details
11/9/2016Q3 2016($0.21)($0.28)ViewN/AView Earnings Details
8/9/2016Q216($0.27)($0.35)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.32)ViewN/AView Earnings Details
3/15/2016Q415($0.23)($0.28)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.27)($0.33)ViewN/AView Earnings Details
5/15/2015Q1 2015($0.26)($0.24)ViewN/AView Earnings Details
4/6/2015Q4 2014($0.23)($0.23)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.13)($1.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ContraFect Corporation (NASDAQ:CFRX)
2017 EPS Consensus Estimate: ($0.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.16)($0.16)($0.16)
Q2 20172($0.17)($0.15)($0.16)
Q3 20172($0.11)($0.10)($0.11)
Q4 20172($0.10)($0.09)($0.10)
(Data provided by Zacks Investment Research)


Dividend History for ContraFect Corporation (NASDAQ:CFRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ContraFect Corporation (NASDAQ:CFRX)
Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 24.45%
Insider Trades by Quarter for ContraFect Corporation (NASDAQ:CFRX)
Institutional Ownership by Quarter for ContraFect Corporation (NASDAQ:CFRX)
Insider Trades by Quarter for ContraFect Corporation (NASDAQ:CFRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Cara M CassinoInsiderBuy8,000$1.24$9,920.00View SEC Filing  
7/25/2017Joshua B MuntnerSVPBuy2,000$1.24$2,480.00View SEC Filing  
7/25/2017Sol J BarerDirectorBuy40,000$1.24$49,600.00View SEC Filing  
7/25/2017Steven C GilmanCEOBuy800$1.24$992.00View SEC Filing  
7/27/2016Steven C GilmanCEOBuy20,000$2.48$49,600.00View SEC Filing  
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32View SEC Filing  
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.41View SEC Filing  
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.16View SEC Filing  
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.37View SEC Filing  
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.92View SEC Filing  
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.30View SEC Filing  
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ContraFect Corporation (NASDAQ:CFRX)
Latest Headlines for ContraFect Corporation (NASDAQ:CFRX)
DateHeadline logoContraFect to Present at the 4th Annual Re-entering Antibacterial Discovery and Development Summit - October 17 at 5:53 PM logoContraFect Appoints Lisa Ricciardi as Chief Operating Officer - October 5 at 7:53 AM logoContraFect Corporation (CFRX) vs. The Competition Critical Analysis - September 29 at 2:36 PM logoContraFect to Present at The MicroCap Conference - GlobeNewswire (press release) - September 29 at 2:11 PM logoContraFect to Present at The MicroCap Conference - September 28 at 6:23 PM logoCritical Comparison: ContraFect Corporation (CFRX) versus Its Peers - September 27 at 4:32 PM logoAnalyzing ContraFect Corporation (CFRX) and Its Competitors - September 23 at 10:20 AM logoAnalyzing ContraFect Corporation (CFRX) and The Competition - September 17 at 10:16 AM logoContraFect to Present at 2017 Cantor Fitzgerald Global Healthcare Conference - September 13 at 6:19 PM logoContraFect to Present at 2017 World Antimicrobial Resistance Congress - September 11 at 5:46 PM logoContrasting ContraFect Corporation (CFRX) & its Rivals - September 10 at 8:38 AM logoContrasting ContraFect Corporation (CFRX) and Tetralogic Pharmaceuticals Corp (TLOG) - September 4 at 2:12 AM logoContraFect Corporation Forecasted to Post Q3 2017 Earnings of ($0.11) Per Share (CFRX) - August 16 at 7:22 AM logo-$0.14 EPS Expected for ContraFect Corporation (CFRX) This Quarter - August 15 at 6:06 PM logoCFRX: Sufficient Capital To Fund Company Past Phase 2 Results for CF-301 - August 14 at 5:29 PM logoEquities Analysts Set Expectations for ContraFect Corporation's Q3 2017 Earnings (NASDAQ:CFRX) - August 11 at 9:48 AM logoContraFect Corporation (CFRX) Issues Earnings Results, Beats Expectations By $0.11 EPS - August 10 at 8:02 PM logoContraFect Announces Second Quarter 2017 Financial Results - August 9 at 5:17 PM logoContraFect Corporation Announces Issuance of Patent for Novel Approach to Treat Influenza Using Inhaled Antibodies - August 3 at 6:37 PM logoContraFect Corporation (CFRX) Expected to Announce Earnings of -$0.16 Per Share - July 28 at 2:30 PM logoCFRX: New Clinical and Microbiological Data Presented on CF-301; New Financing To Fund Company Past Phase 2 Results for CF-301 - July 27 at 4:33 PM logoInsider Buying: ContraFect Corporation (NASDAQ:CFRX) Director Buys 40,000 Shares of Stock - July 26 at 8:48 PM logoContraFect Corporation Prices $40 Million Public Offering of Common Stock and Warrants - July 20 at 6:52 PM logoContraFect (CFRX) Commences Public Offering of Common Stock and Warrants - July 19 at 6:17 PM logoContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants - July 19 at 6:17 PM logoAnalyzing ContraFect Corporation (NASDAQ:CFRX) and Aevi Genomic Medicine (GNMX) - July 11 at 6:22 PM logoContraFect (CFRX) Begins Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia - May 26 at 3:45 AM logoContraFect Shares Bounce on Initiating Mid-Stage Trial for Staph Infections - May 26 at 3:45 AM logoCONTRAFECT CORP Files SEC form 10-K, Annual Report - March 15 at 9:37 PM logoContraFect's (CFRX) Chairman and Takes Temporary Medical Leave - March 14 at 9:09 PM logoCONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - March 14 at 11:34 AM logoContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave - March 13 at 12:44 PM logoLisa Ricciardi to Join Board of Directors - February 16 at 9:40 AM logo7:02 am ContraFect reports investigational drug product lot did not meet manufacturing release specifications; now expects to initiate the Phase 2 study of CF-301 in Staph aureus in mid-2017 - January 6 at 4:39 PM logoContraFect (CFRX) Receives $2.1M PRMRP-Related Development Award - November 17 at 3:24 PM logoCONTRAFECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - August 9 at 12:01 PM logoCONTRAFECT CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements an - July 27 at 9:31 AM logoContraFect (CFRX) Prices 14M Common Stock, Warrants Offering for Proceeds of ~$35M - July 22 at 4:12 PM logoCONTRAFECT CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or Principal - July 21 at 5:30 PM logoCONTRAFECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits - June 27 at 6:10 AM logoQ1 2016 ContraFect Corp Earnings Release - Time Not Supplied - May 10 at 7:07 AM logoCONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers - April 12 at 6:03 AM



ContraFect Corporation (CFRX) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.